OptimizeRx (NASDAQ:OPRX - Get Free Report) had its target price dropped by equities research analysts at JMP Securities from $16.00 to $8.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has a "market outperform" rating on the stock. JMP Securities' target price points to a potential upside of 97.04% from the company's previous close.
OPRX has been the subject of a number of other research reports. Royal Bank of Canada dropped their target price on OptimizeRx from $17.00 to $14.00 and set an "outperform" rating for the company in a research report on Friday, August 16th. B. Riley assumed coverage on shares of OptimizeRx in a report on Thursday, July 25th. They issued a "buy" rating and a $18.50 price objective for the company. Finally, Barclays reduced their target price on shares of OptimizeRx from $15.00 to $11.00 and set an "equal weight" rating on the stock in a report on Monday, August 12th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, OptimizeRx presently has a consensus rating of "Moderate Buy" and a consensus price target of $10.42.
View Our Latest Analysis on OptimizeRx
OptimizeRx Price Performance
Shares of OptimizeRx stock traded down $2.09 on Thursday, reaching $4.06. The stock had a trading volume of 1,961,315 shares, compared to its average volume of 140,475. The business's 50 day moving average is $6.75 and its two-hundred day moving average is $9.07. The company has a market cap of $74.39 million, a P/E ratio of -4.18 and a beta of 1.32. OptimizeRx has a 1 year low of $3.95 and a 1 year high of $16.65. The company has a current ratio of 3.07, a quick ratio of 3.07 and a debt-to-equity ratio of 0.27.
Institutional Trading of OptimizeRx
Hedge funds have recently bought and sold shares of the company. First Light Asset Management LLC increased its stake in shares of OptimizeRx by 5.1% in the 2nd quarter. First Light Asset Management LLC now owns 1,826,961 shares of the company's stock worth $18,270,000 after purchasing an additional 89,377 shares in the last quarter. Vanguard Group Inc. increased its position in OptimizeRx by 0.6% in the first quarter. Vanguard Group Inc. now owns 1,027,293 shares of the company's stock worth $12,482,000 after buying an additional 6,291 shares in the last quarter. AWM Investment Company Inc. raised its stake in shares of OptimizeRx by 4.0% in the first quarter. AWM Investment Company Inc. now owns 853,042 shares of the company's stock worth $10,364,000 after buying an additional 33,000 shares during the period. Blair William & Co. IL lifted its position in shares of OptimizeRx by 5.6% during the 1st quarter. Blair William & Co. IL now owns 782,573 shares of the company's stock valued at $9,508,000 after buying an additional 41,469 shares in the last quarter. Finally, Rice Hall James & Associates LLC lifted its position in shares of OptimizeRx by 24.0% during the 3rd quarter. Rice Hall James & Associates LLC now owns 615,441 shares of the company's stock valued at $4,751,000 after buying an additional 119,306 shares in the last quarter. Hedge funds and other institutional investors own 76.47% of the company's stock.
About OptimizeRx
(
Get Free Report)
OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.
Featured Stories
Before you consider OptimizeRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OptimizeRx wasn't on the list.
While OptimizeRx currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.